Search research articles
Contact Us
Filters
Showing results (131-140 of 143) with videos related to
Page
of 15
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Melanoma Research
|
March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)
Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2023
The New NCI Precision Medicine Trials
Lyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
Christina Yap, Olga Solovyeva, Johann de Bono, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
Christina Yap, Jan Rekowski, Moreno Ursino, et al.
Cancer Chemotherapy and Pharmacology
|
April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
Julia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Eclinicalmedicine
|
January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials
Jan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine
|
January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols
Moreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Journal of the National Cancer Institute
|
April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A Conley, Lou Staudt, Naoko Takebe, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 143) with videos related to
Sort By:
Page
of 15
Proceedings of the National Academy of Sciences of the United States of America
|
November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Melanoma Research
|
March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)
Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2023
The New NCI Precision Medicine Trials
Lyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
Christina Yap, Olga Solovyeva, Johann de Bono, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
Christina Yap, Jan Rekowski, Moreno Ursino, et al.
Cancer Chemotherapy and Pharmacology
|
April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
Julia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Eclinicalmedicine
|
January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials
Jan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine
|
January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols
Moreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Journal of the National Cancer Institute
|
April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A Conley, Lou Staudt, Naoko Takebe, et al.
Page
of 15